InflaRX Dives 13.0137% Pre-Market Amid Biotech Sector Volatility and Profit-Taking

InflaRx opened the pre-market session on November 14, 2025, with a sharp 13.0137% decline, signaling a significant drop in investor confidence ahead of regular trading hours.

The abrupt selloff follows a period of heightened volatility in the biotech sector, though no immediate corporate announcements or regulatory updates were reported to directly trigger the move. Market participants speculate that broader risk-off sentiment and sector-wide profit-taking may have contributed to the decline, though specific catalysts remain unconfirmed.

Backtest assumptions suggest a potential short-term momentum strategy could have been triggered by the pre-market weakness, with stop-loss levels and volatility indicators aligning with the observed price action. However, execution risks remain elevated given the lack of clarity on underlying fundamentals.

Investors are now closely monitoring the stock's behavior in regular trading hours, as it could serve as a barometer for broader market sentiment in the biotech space. Analysts remain divided on the sustainability of the current downward trend, with some advocating for a wait-and-see approach while others propose short-term hedging strategies based on technical indicators.